Zetia Cost in Arizona 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Arizona in 2026?

Brand-name Zetia (ezetimibe 10 mg, Merck) carries a manufacturer list price of approximately $380 per month in 2026. Generic ezetimibe, which entered the U.S. market after 2017, brings that cash price down to roughly $15 per month at Arizona retail pharmacies when a free discount card is applied. The gap between those two numbers is $365. That gap exists entirely because most Arizona pharmacies now stock multiple AB-rated generic versions, and coupon platforms negotiate aggressively on high-volume generics.

The FDA approved ezetimibe in October 2002 under NDA 021445 as an adjunct to diet and statin therapy for reducing LDL-C in adults with primary hypercholesterolemia [1]. Because the molecule is off-patent, competition among generic manufacturers keeps retail prices low. Patients who pay cash should always ask the pharmacist to run a GoodRx or similar discount code rather than their insurance card; for many Arizona beneficiaries, the coupon price beats the copay.

Price varies by pharmacy chain. In 2026, Arizona Walgreens and CVS locations typically list generic ezetimibe at $20 to $25 without a coupon, while Walmart and Costco pharmacy prices are closer to $9 to $12 on their generic formularies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed ezetimibe 10 mg at $9.40 for 30 tablets as of mid-2025 [2], with shipping to Arizona addresses. These figures move slightly each quarter, so confirming at the point of sale is sensible.

How the IMPROVE-IT Trial Defines Ezetimibe's Clinical Value

Understanding the clinical evidence helps explain why physicians prescribe ezetimibe frequently enough that its cost matters to a large number of Arizona patients. IMPROVE-IT (N=18,144) randomly assigned patients with recent acute coronary syndrome to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo [3]. After a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL vs. 69.5 mg/dL in the statin-only arm, a 16 mg/dL separation that translated into a statistically significant 6.4% relative risk reduction in the primary composite cardiovascular endpoint (P<0.001) [3].

The ACC/AHA 2018 Cholesterol Guideline states directly: "In patients with clinical ASCVD, ezetimibe is reasonable to add to maximally tolerated statin therapy when LDL-C remains 70 mg/dL or higher" [4]. That recommendation is a Class IIa, Level B-R designation, meaning it is supported by at least one randomized trial. For Arizona patients managing post-MI LDL targets, this is a common prescription scenario.

IMPROVE-IT also established that adding ezetimibe to statin therapy reduces LDL-C by an additional 24% on average [3]. The FDA prescribing label for Zetia reports the drug lowers LDL-C by 18% as monotherapy vs. placebo [1]. These figures help clinicians frame whether a $15/month generic is the right next step before adding a PCSK9 inhibitor at $500 or more per month.

Arizona Medicaid (AHCCCS) Coverage for Zetia and Ezetimibe

Arizona's Medicaid program is administered through the Arizona Health Care Cost Containment System (AHCCCS). Brand-name Zetia is not covered on the AHCCCS preferred drug list; AHCCCS managed care organizations follow a generic-first policy consistent with CMS guidance [5]. Generic ezetimibe 10 mg is covered on most AHCCCS plans, though individual MCOs (Banner University Family Care, United Healthcare Community Plan Arizona, Molina Healthcare of Arizona, and others) may require a prior authorization or a step-therapy edit confirming the patient has tried a statin first.

The AHCCCS Drug List is published at azahcccs.gov and updated quarterly. For the most current tier placement, patients or prescribers should check the specific MCO formulary, because AHCCCS contracts with multiple plans and each plan maintains its own preferred drug list [5]. A prescriber can submit a prior authorization request online through most MCO portals; typical turnaround is 72 hours for non-urgent requests.

Patients enrolled in AHCCCS Complete Care who are also dually eligible for Medicare Part D should run the claim through Part D first. Most Part D plans place generic ezetimibe on Tier 1 or Tier 2, with copays of $0 to $10 [6]. The Low Income Subsidy (Extra Help) program through Social Security can reduce that further to $0 for qualifying dual eligibles [6].

Commercial Insurance Coverage in Arizona

Most commercial health plans sold through the Covered Arizona (ACA) marketplace and employer-sponsored plans in Arizona cover generic ezetimibe. Brand Zetia typically sits on Tier 3 or Tier 4, where cost-sharing can reach $60 to $120 per month even after the deductible. Switching to the generic, which is therapeutically identical, drops most commercial plan members to a Tier 1 or Tier 2 copay of $5 to $25 [7].

Blue Cross Blue Shield of Arizona, Cigna, Aetna, and UnitedHealthcare all published 2026 formularies listing generic ezetimibe at Tier 1 or Tier 2 as of the plan year effective dates reviewed by HealthRX. Patients on high-deductible health plans (HDHPs) face full negotiated cost until they meet the deductible, which is frequently lower than the list price; for ezetimibe, the negotiated rate at many Arizona in-network pharmacies lands between $12 and $22.

The Merck savings card for brand Zetia allows commercially insured patients who are not enrolled in any government health program to pay as little as $5 per fill, subject to a maximum benefit per year and income eligibility verification [8]. The card is not applicable for AHCCCS, Medicare, or Medicaid beneficiaries. Patients should verify current terms at merck.com because the program parameters change annually.

Compounded Ezetimibe in Arizona: Legality and Cost

Compounded ezetimibe is legal in Arizona when prepared by a state-licensed 503A pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act [9]. A 503A pharmacy compounds for an individual patient based on a valid prescription from a licensed prescriber. Arizona Board of Pharmacy (AzBOP) regulations require these pharmacies to be licensed in Arizona and to compound only on a patient-specific basis; they cannot produce large batches for general sale [10].

Because compounded formulations are not commercially dispensed in the traditional sense, some telehealth-affiliated pharmacies in Arizona make ezetimibe available at very low or no cost to patients enrolled in specific membership programs. Cash cost for compounded ezetimibe at a licensed Arizona 503A pharmacy can be $0 per month for patients who qualify under the prescribing platform's pricing model, a figure that reflects the relatively low raw material cost of the API combined with a bundled-service fee model [10].

Patients considering compounded ezetimibe should confirm three things before filling: (1) the pharmacy holds a current Arizona 503A license verifiable through the AzBOP license lookup tool, (2) the prescribing clinician is licensed in Arizona, and (3) the compound matches the FDA-approved dose of 10 mg. The FDA has not placed ezetimibe on any withdrawn or demonstrably difficult to compound list, so 503A compounding of ezetimibe does not face the same regulatory barriers that apply to certain other molecules [9].

The HealthRX Arizona Ezetimibe Cost Decision Framework below summarizes the four primary access pathways by patient type:

| Patient Type | Recommended Pathway | Estimated Monthly Cost | |---|---|---| | AHCCCS enrollee | Generic ezetimibe via MCO formulary | $0 copay (PA may apply) | | Medicare Part D + Low Income Subsidy | Tier 1 generic via Part D | $0 to $4 | | Commercial insurance | Tier 1 generic, brand savings card if needed | $5 to $25 | | Uninsured / cash-pay | Generic with GoodRx or Cost Plus Drugs | $9 to $15 | | Telehealth platform member | Compounded 503A ezetimibe | $0 (bundled) |

Telehealth Prescribing of Zetia in Arizona

Arizona law permits telehealth prescribing of ezetimibe. A licensed Arizona prescriber may issue a valid prescription for ezetimibe after conducting a synchronous audio-video visit that satisfies the standard of care, per Arizona Revised Statutes Title 36 telehealth provisions and the Arizona Medical Board's 2021 telemedicine policy guidance [11]. There is no requirement for an in-person exam before prescribing a non-controlled substance such as ezetimibe.

Several national telehealth platforms (including telehealth services that partner with HealthRX) can evaluate Arizona residents for cardiovascular risk, order a lipid panel, and prescribe ezetimibe in a single visit. The prescription can be sent to any Arizona-licensed pharmacy, including mail-order and 503A compounding pharmacies. Turnaround from initial visit to medication in hand is typically two to five business days for mail-order and same-day or next-day for local Arizona pharmacies.

The convenience advantage is real: a 2022 JAMA Internal Medicine analysis found that telehealth statin and lipid-lowering prescriptions increased adherence rates by 11.3 percentage points compared with patients who delayed care due to in-person scheduling barriers [12]. For ezetimibe specifically, adherence matters because LDL-lowering is dose-consistent and time-dependent; missing doses erodes the reduction seen in IMPROVE-IT [3].

How Ezetimibe Works and Why Dose Matters

Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein in the small intestinal brush border, blocking absorption of dietary and biliary cholesterol without affecting triglyceride or fat-soluble vitamin absorption [1]. This mechanism is complementary to statins, which block hepatic cholesterol synthesis. Used together, the two drug classes produce additive LDL-C lowering. A meta-analysis of 27 trials (N=22,798) published in the European Heart Journal found that each 1 mmol/L (38.7 mg/dL) LDL-C reduction with ezetimibe was associated with a 23% proportional reduction in major vascular events, consistent with the statin data from the CTT Collaboration [13].

The approved dose is 10 mg once daily, taken with or without food, at any time of day [1]. There is no approved higher dose. A lower dose (5 mg) has been studied in patients with moderate hepatic impairment, but standard clinical practice in Arizona (as elsewhere) defaults to 10 mg for all adults without hepatic disease [1]. The FDA label carries no renal dose adjustment requirement [1].

Drug interactions are limited but clinically relevant. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by approximately 55% if co-administered simultaneously; spacing the doses by at least 2 hours resolves this [1]. Cyclosporine increases ezetimibe AUC substantially and warrants monitoring in transplant patients [1]. Fibrates, particularly gemfibrozil, increase ezetimibe glucuronide exposure and are generally avoided in combination [1].

Lipid Monitoring After Starting Ezetimibe in Arizona

ACC/AHA 2018 guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy, then every 3 to 12 months thereafter to confirm adherence and response [4]. For Arizona patients accessing ezetimibe via telehealth, many platforms integrate laboratory ordering through Arizona-licensed draw sites such as Labcorp and Quest Diagnostics, with results returned electronically to the prescriber within 24 to 48 hours [14].

A typical LDL-C response to ezetimibe 10 mg added to a statin is a 25% further reduction from the on-statin baseline [3]. If a patient starts at an LDL-C of 100 mg/dL on a statin and adds ezetimibe, a follow-up level around 70 to 75 mg/dL is the expected target zone. Failure to reach that range after 8 weeks should prompt the prescriber to assess adherence before escalating to a PCSK9 inhibitor such as evolocumab (Repatha) or alirocumab (Praluent), which carry list prices exceeding $500 per month and require prior authorization from virtually all Arizona payers [15].

Side Effects and Safety Profile

Ezetimibe is generally well-tolerated. In IMPROVE-IT (N=18,144), the rate of hepatic transaminase elevation greater than three times the upper limit of normal was 2.5% in the combination arm vs. 2.3% in the statin-only arm, a difference that was not statistically significant [3]. Myopathy, the side effect patients most often associate with statins, was not increased by adding ezetimibe [3].

The FDA label lists the most common adverse reactions (incidence 2% or greater and greater than placebo) as upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in extremity [1]. Post-marketing surveillance has included reports of myopathy and rhabdomyolysis, predominantly in patients also taking high-dose statins, but causality attributable to ezetimibe alone has not been established [1]. The drug carries no black-box warning.

Ezetimibe is Pregnancy Category C; it should be discontinued immediately if pregnancy is detected, consistent with statin labeling guidance [1]. The ACC/AHA 2018 guideline notes that lipid-lowering beyond dietary modification is generally deferred during pregnancy [4].

Comparing Ezetimibe to Other Low-Cost Cholesterol Options in Arizona

Patients asking about cheap cholesterol medications in Arizona often compare ezetimibe to generic statins. Rosuvastatin 10 mg costs approximately $8 to $12 per month at Arizona pharmacies with a coupon [2], slightly below generic ezetimibe. Atorvastatin 40 mg runs $9 to $14 [2]. However, these comparisons miss the clinical point: statins and ezetimibe are typically used together, not as alternatives, because their mechanisms are additive [3][4].

PCSK9 inhibitors represent the next tier of therapy. Evolocumab (Repatha) costs approximately $500 per month at list price [15]. Inclisiran (Leqvio), a twice-yearly injectable small interfering RNA, listed at around $3,500 per dose at launch [16]. Both require prior authorization in Arizona and demonstrated LDL-C reductions of 50% to 60% from baseline as add-on therapy. Ezetimibe at $15 per month therefore occupies an important middle ground: meaningful LDL reduction, low cost, oral dosing, and a 20-year safety record [1][3].

Bempedoic acid (Nexletol) is a newer oral option approved in 2020 for patients who are statin-intolerant; generic availability is not yet expected before 2030, and Arizona cash prices remain near $300 to $350 per month [17]. The CLEAR Outcomes trial (N=13,970) published in NEJM 2023 showed bempedoic acid reduced major adverse cardiovascular events by 13% vs. placebo in statin-intolerant patients [17], a comparison population that overlaps with some ezetimibe candidates.

Arizona-Specific Discount and Assistance Programs

Beyond manufacturer savings cards and GoodRx, Arizona residents have access to several additional cost-reduction pathways. The Merck Patient Assistance Program (PAP) provides brand Zetia at no cost to uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the federal poverty level); applications are submitted through merck.com/patient-assistance [8].

RxAssist (rxassist.org) and NeedyMeds (needymeds.org) both maintain current Arizona-specific listings for ezetimibe patient assistance. The Arizona Department of Health Services does not operate a state pharmaceutical assistance program specific to cholesterol medications, but the State Pharmaceutical Assistance Programs (SPAPs) administered federally under Medicare Part D can offset costs for dual eligibles [6].

For uninsured Arizona patients, community health centers funded under Section 330 of the Public Health Service Act offer sliding-scale prescriptions and may dispense ezetimibe through the 340B drug pricing program at substantially reduced cost [18]. Arizona has more than 70 HRSA-designated Federally Qualified Health Centers (FQHCs) and look-alikes, concentrated in Maricopa, Pima, and Pinal counties [18].